EQ-3
2.8.2016 10:02:00 CEST | Business Wire | Press release
According to the renowned market research company Berg Insight, eQ-3 is the European market leader in smart home for the third time in a row. The company jumps ahead with a market share of 35 percent in installed whole home solutions: About 285,000 households in Europe already use whole home solutions from eQ-3. With regard to smart thermostats, there are over 560,000 households already. In total eQ-3 has shipped more than 18 million wireless home control devices.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005208/en/
The market research company Berg Insight confirms the company located in Leer, Germany, as market leader in its fourth edition of the “Smart Homes and Home Automation” study. Whole home systems by eQ-3 are already installed in around 285,000 households in Europe today. These include more than six million devices based on the Homematic product line as well as the next smart home generation Homematic IP and major OEM solutions such as RWE smart home. The company has recorded continuous growth over many years in the smart home area, largely thanks to the product line Homematic introduced almost ten years ago. In the last three years, Homematic growth exceeded 75 percent per year, even with the already large installed base. According to Berg Insight, Homematic has three times more installed whole home systems in the consumer segment than all KNX manufacturers together.
The same positive trend becomes apparent when looking at the smart thermostats sector: Over 560,000 households in Europe use smart thermostats from eQ-3 already today, representing a market share of 41 percent. According to Berg Insight, the heating control system MAX! is used in 320,000 households.
In contrast to other smart thermostat solutions, eQ-3 solutions such as Homematic IP, Homematic, and MAX! provide heating control not only for the entire home, but on a room-by-room basis. Therefore, the energy is controlled based on the actual usage of rooms and associated need for heating rooms individually. This results in significantly increased energy savings. Furthermore, while other solutions typically consist of a boiler switch, a thermostat, and a gateway only, the eQ-3 solutions additionally include radiator thermostats, wall thermostats, and window sensors and other devices. When considering that a typical eQ-3 heating solution has eight to nine versus two to three devices, the European market share of eQ-3 based on the number of individual devices would be even above 70 percent.
Another major difference to other smart heating solutions is that eQ-3 provides a smooth extension path to full smart home solutions today, seamlessly adding security and alarm, light and shade, access control and many other applications for mass consumer deployment. The eQ-3 smart home products are marketed under the Homematic IP, Homematic, and MAX! brands through a wide variety of channels, including specialty retailers, Amazon and many online stores, large CE retailers, DIY, and installers that are served by our own field sales force together with the leading electrical wholesaler Sonepar. Additionally, eQ-3 is the technology and product provider behind smart home offerings from RWE, Deutsche Telekom and many other OEMs. With Homematic IP and an earlier OEM solution, eQ-3 is the pioneer in delivering an all-IPv6 smart home solution. Further strengths of Homematic IP are its ease-of-use, confirmed best-in-class security, and a leading position in data privacy thanks to a free, anonymously operated cloud service.
Homematic IP by eQ-3
About eQ-3:
eQ-3 is one of the leading innovation and technology companies for home control and consumer electronics. With more than 200 different types of products, eQ-3 today provides the largest product portfolio in the industry and has placed more than 18 million wireless solutions in more than 600,000 households on the market. This makes eQ-3 the European market leader in smart home technology based on the number of whole home solutions and electronic radiator thermostats installed. Homematic is the leading smart home platform with more than 80 devices and open communication interfaces. Homematic IP, the next generation of Homematic, is based on the Internet standard IPv6 as open platform and fully compatible with the devices of the Homematic family. The products are designed and developed at the headquarters in Leer, Germany. The final manufacturing takes place in the own production plant in South China. The ELV/eQ-3 group has been family owned since its foundation. The eQ-3 group was founded in 2007 as a spin-off from the ELV Elektronik AG, existing since 1978. Further information: www.eQ-3.de , www.HomeMatic.com , www.homematic-ip.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005208/en/
Contact:
Press contact:
Sinje Salamon
eQ-3 AG
Marketing
Manager
+49 (491) 6008 - 626
sinje.salamon@eq-3.de
or
PR
agency:
Benjamin Kolthoff
P.U.N.K.T. Gesellschaft
für Public
Relations mbH
+49 (40) 85 37 60 - 29
bkolthoff@punkt-pr.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
